The FDA on November 6, 2017, granted regular approval to ALECENSA®, for treatment of patients with Anaplastic Lymphoma Kinase (ALK)-positive metastatic Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test. ALECENSA® is a product of Hoffmann-La Roche, Inc./Genentech, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
